Organon Believes It Can Beat Out Other Humira Rivals In US

PBMs Likely To List ‘Two Or Three’ Adalimumab Biosimilars On Formulary

 
• By Dave Wallace

As the biosimilars industry awaits several US adalimumab launches in 2023, Organon has set out the reasons why it believes it can stand out from its competitors.

Red Chess Pawn Standing Out From Row Of Black Pawns
Organon thinks it can stand out from the competition on adalimumab • Source: Shutterstock

More from Biosimilars

More from Products